cancer

A unique collection of 7234 compounds with anti-cancer activity for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 1268 cancer cellular metabolism related compounds for cancer research and high throughput screening (HTS) and high content screening (HCS);

A unique collection of 3188 compounds with known anti-cancer activity for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 1702 compounds with anti-lung cancer therapeutic activity or targeting lung cancer’s major signaling pathways, can be used for anti-lung cancer drug discovery and mechanism study；

A unique collection of 406 cancer cell differentiation inducing compounds for high throughput and high content screening;

A unique collection of 2238 pancreatic cancer related compounds can be used in HTS and HCS;

A unique collection of 1779 approved anti-cancer drugs for high throughput screening (HTS) and high content screening (HCS);

1545 compounds associated with colorectal cancer that can be used for high-throughput and high-content screening.

A unique collection of 1939 compounds with anti-breast cancer therapeutic activity or targeting breast cancer’s major signaling pathways, can be used for anti-breast cancer drug discovery and mechanism study；

A collection of 382 TCM monomers with anti-colorectal activity. An effective tool for drug development and pharmacological studies.

A unique collection of 2545 anti-cancer compounds for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 3080 anticancer drugs for high throughput screening (HTS) and high content screening (HCS);

Well-chosen 1468 anti-tumor compounds with unique structures;

2070 compounds associated with prostate cancer that can be used for high-throughput and high-content screening.

1787 species of compounds related to liver cancer that can be used in anti-liver cancer drug development and pharmacological studies.

A unique collection of 1867 compounds with anti-ovarian cancer therapeutic activity, can be used for anti-ovarian cancer drug discovery and pharmacological study;

A unique collection of 1283 endogenous metabolism-related compounds for research in endogenous metabolism-related diseases and drug screening.

A collection of 499 selected human endogenous metabolites for high throughput and high content screening.

A unique collection of 812 promising or approved mitochondria-targeted compounds including Idebenone, the only approved drug targeting mitochondria, for research in mitochondrial medicine;

A unique collection of 500 natural alkaloids can be used for high throughput and high content screening；

A unique collection of 343 protease and proteasome inhibitors for research in chemical genomics, and drug screening;

A unique collection of 3404 compounds in clinical trial phases for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 910 DNA Damage & Repair related compounds for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 1544 metabolism diseases related compounds for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 622 natural terpenes and terpenoids can be used for high throughput and high content screening；

A unique collection of 514 flavonoids can be used for high throughput and high content screening；

A unique collection of 485 PPI-related compounds for drug screening;

A unique collection of 635 natural polyphenolic compounds for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 492 compounds targeting lipid metabolism, can be used for high-throughput screening (HTS) and high-content screening (HCS).

A unique collection of 677 cell cycle related compounds for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 2755 compounds (TCM monomers) sourcing from traditional Chinese Medicines, is a powerful tool for drug discovery and research in mechanism；

Well-chosen 953 compounds related to epigenetic regulation for research in epigenetics, high throughput screening (HTS) and high content screening (HCS) for new drugs;

A unique collection of 449 compounds acting on immune-oncology therapeutic targets can be used for high throughput and high content screening；

791 peptides can be used in peptide drug development and signaling transduction and mechanism study;

A unique collection of 250 compounds targeting chromatin remodeling pathway for high throughput screening (HTS) and high content screening (HCS);

48 Chemotherapeutic drugs that can be used for high-throughput and high-content screening.

119 tumor-targeted drugs that can be used for high-throughput and high-content screening.

702 glycometabolism-related comounds, can be used for HTS and HCT;

128 methylation-related compounds that can be used for high-throughput and high-content screening.

A unique collection of 420 compounds targeting PI3K Akt mTOR signaling for research in PI3K Akt mTOR signaling, and drug discovery in diseases involved with PI3K Akt mTOR signaling;

A unique collection of 779 ferroptosis signaling pathway related compounds, a powerful tool for new target identification, drug discovery, and mechanism study；

A unique collection of 514 compounds related to hematologic diseases for high throughput screening (HTS) and high content screening (HCS);

Oxidative stress reflects an imbalance between the systemic manifestation of reactive oxygen species (ROS) and a biological system's ability to readily detoxify the reactive intermediates or repair the resulting damage. Disturbances in the normal redox state of cells can cause toxic effects through the production of peroxides and free radicals that damage all components of the cell, including proteins, lipids, and DNA. In humans, oxidative stress is thought to be involved in the development of atherosclerosis, heart failure, myocardial infarction, cancer, infection etc. Antioxidants are a class of compounds that counteract oxidative stress and reduce oxidative damage. The TargetMol Antioxidant Compound Library is a unique collection of 1314 small molecules with inhibitory effects on oxidative stress and is a useful tool for high-throughput screening and high-content screening in the study of oxidative stress.

A unique collection of 685 microbial natural products for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 1772 natural products with known anti-cancer activity for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 1920 covalent Inhibitors and other molecules with common warheads like chloroacetyl，2-Chloropropionyl，Acryloyl，sulfonyl fluoride, alkyne，acrylamide, ketocarbonyl，disulfide bond, etc.

A unique collection of 1760 apoptosis-related compounds for apoptosis research, research in tumorigenesis, and anti-cancer drug screening;

A unique collection of 759 cytoskeleton-related compounds, can be used for HTS and HCS；

A unique collection of 263 kinase inhibitors regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.

A unique collection of 565 glutamine metabolism related compounds can be used for high throughput screening (HTS) and high content screening (HCS), and also is an effective tool for research in glutamine metabolism and cancer;